Long-term cardiovascular health in adult cancer survivors

Publication date

2017-11

Authors

Naaktgeboren, W R
Linschoten, MarijkeORCID 0000-0002-4541-080X
De Graeff, AlexanderISNI 0000000392189877
van Rhenen, Anna
Cramer, Maarten JISNI 0000000390984527
Asselbergs, Folkert WORCID 0000-0002-1692-8669ISNI 0000000391548591
Maas, Angela H E M
Teske, Arco J.ISNI 0000000396645403

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

taverne

Abstract

The number of cancer survivors has tremendously increased over the past decades as a result of aging of the population and improvements in early cancer detection and treatment. Ongoing successes in cancer treatment are expected to result in a further increase in the number of long-term survivors. However, cancer treatment can have detrimental cardiovascular side-effects that impact morbidity and mortality, reducing quality of life in cancer survivors. The spectrum of radiotherapy- and chemotherapy-induced cardiovascular disease is broad, varying from subclinical valvular dysfunction to overt congestive heart failure, and such effects may not be apparent for more than twenty years after the initial cancer treatment. Awareness of these long-term side-effects is of crucial value in the management of these patients, in order to reduce the impact of cardiovascular morbidity and mortality. This review provides a comprehensive overview of the long-term cardiovascular complications of cancer treatments (radiotherapy and chemotherapy) in adult cancer survivors.

Keywords

Cardiotoxicity, Cancer survivor, Radiotherapy, Chemotherapy, Cardiovascular disease, Cardio-oncology, Taverne, General Biochemistry,Genetics and Molecular Biology, Obstetrics and Gynaecology

Citation

Naaktgeboren, W R, Linschoten, M, de Graeff, A, V Rhenen, A, Cramer, M J, Asselbergs, F W, Maas, A H E M & Teske, A J 2017, 'Long-term cardiovascular health in adult cancer survivors', Maturitas, vol. 105, pp. 37-45. https://doi.org/10.1016/j.maturitas.2017.05.014